The Caldwell Partners International Announces Results of Vote for Election of Directors

TORONTO, March 3, 2017 /PRNewswire/ – Retained executive search firm The Caldwell Partners International Inc. (TSX: CWL) reported that at its Annual Meeting of shareholders on March 2, 2017 there was 1 shareholder voting in person holding 700 Voting Common Shares and 94 shareholders voting by proxy holding 6,351,920 Voting Common Shares, representing in total 95 shareholders holding 6,352,620 Voting Common Shares, and 31.56% of the total number of Voting Common Shares outstanding.

Each of the directors listed as nominees in the management proxy circular dated January 11, 2017 were elected directors of the Corporation until the next Annual Meeting.

The results of the vote for the election of directors and reconfirmation of the shareholder rights plan are as follows:

* As the vote for each motion was taken by a show of hands, the number of votes disclosed reflects only those proxies received by management in advance of the meeting, plus any shares voted by a show of hands at the meeting in respect of which the shareholder voted against, or withheld authority.

About Caldwell Partners
Caldwell Partners is a leading international provider of executive search and has been for more than 45 years. As one of the world’s most trusted advisors in executive search, the firm has a sterling reputation built on successful searches for boards, chief and senior executives, and selected functional experts. With offices and partners across North America, Europe, Latin America and Asia Pacific, the firm takes pride in delivering an unmatched level of service and expertise to its clients.

The Caldwell Partners’ Common shares are listed on The Toronto Stock Exchange (TSX: CWL). Please visit our website at www.caldwellpartners.com for further information.

SOURCE The Caldwell Partners International Inc.

The Caldwell Partners International Announces Results of Vote for Election of Directors

TORONTO, March 3, 2017 /PRNewswire/ – Retained executive search firm The Caldwell Partners International Inc. (TSX: CWL) reported that at its Annual Meeting of shareholders on March 2, 2017 there was 1 shareholder voting in person holding 700 Voting Common Shares and 94 shareholders voting by proxy holding 6,351,920 Voting Common Shares, representing in total 95 shareholders holding 6,352,620 Voting Common Shares, and 31.56% of the total number of Voting Common Shares outstanding.

Each of the directors listed as nominees in the management proxy circular dated January 11, 2017 were elected directors of the Corporation until the next Annual Meeting.

The results of the vote for the election of directors and reconfirmation of the shareholder rights plan are as follows:

* As the vote for each motion was taken by a show of hands, the number of votes disclosed reflects only those proxies received by management in advance of the meeting, plus any shares voted by a show of hands at the meeting in respect of which the shareholder voted against, or withheld authority.

About Caldwell Partners
Caldwell Partners is a leading international provider of executive search and has been for more than 45 years. As one of the world’s most trusted advisors in executive search, the firm has a sterling reputation built on successful searches for boards, chief and senior executives, and selected functional experts. With offices and partners across North America, Europe, Latin America and Asia Pacific, the firm takes pride in delivering an unmatched level of service and expertise to its clients.

The Caldwell Partners’ Common shares are listed on The Toronto Stock Exchange (TSX: CWL). Please visit our website at www.caldwellpartners.com for further information.

SOURCE The Caldwell Partners International Inc.

The Caldwell Partners International Announces Results of Vote for Election of Directors

TORONTO, March 3, 2017 /PRNewswire/ – Retained executive search firm The Caldwell Partners International Inc. (TSX: CWL) reported that at its Annual Meeting of shareholders on March 2, 2017 there was 1 shareholder voting in person holding 700 Voting Common Shares and 94 shareholders voting by proxy holding 6,351,920 Voting Common Shares, representing in total 95 shareholders holding 6,352,620 Voting Common Shares, and 31.56% of the total number of Voting Common Shares outstanding.

Each of the directors listed as nominees in the management proxy circular dated January 11, 2017 were elected directors of the Corporation until the next Annual Meeting.

The results of the vote for the election of directors and reconfirmation of the shareholder rights plan are as follows:

* As the vote for each motion was taken by a show of hands, the number of votes disclosed reflects only those proxies received by management in advance of the meeting, plus any shares voted by a show of hands at the meeting in respect of which the shareholder voted against, or withheld authority.

About Caldwell Partners
Caldwell Partners is a leading international provider of executive search and has been for more than 45 years. As one of the world’s most trusted advisors in executive search, the firm has a sterling reputation built on successful searches for boards, chief and senior executives, and selected functional experts. With offices and partners across North America, Europe, Latin America and Asia Pacific, the firm takes pride in delivering an unmatched level of service and expertise to its clients.

The Caldwell Partners’ Common shares are listed on The Toronto Stock Exchange (TSX: CWL). Please visit our website at www.caldwellpartners.com for further information.

SOURCE The Caldwell Partners International Inc.

Foothills Exploration, Inc (FTXP: OTCQB) | Foothills Exploration, Inc. Announces Two Additions to Its Senior Management Team

Mar 03, 2017

OTC Disclosure & News Service

DENVER, March 03, 2017 (GLOBE NEWSWIRE) — Foothills Exploration, Inc. (OTCQB:FTXP) (the “Company” or “Foothills”), an independent oil and gas exploration and production company engaged in the acquisition and development of properties in the Rockies and Gulf Coast, today announced the appointment of Christopher Jarvis and Kevin Sylla to its management team. Mr. Jarvis is a current Director of Foothills Exploration and will take on the full-time role of Executive Vice President of Finance for the Company and Vice President of Risk Management for Foothills Petroleum Inc., a wholly owned subsidiary. Kevin J. Sylla has been appointed Director and Chief Executive Officer of Foothills Petroleum, Inc. which oversees the Company’s regional operations.

“Both of these new appointments further strengthen our team of oil and gas industry professionals,” stated B.P. Allaire, CEO of Foothills Exploration, Inc. “Chris and Kevin bring proven track records of financial and operational success. Their addition bolsters our corporate structure to meet the needs of our business and help realize the value of our significant oil and gas assets. Both gentlemen will be instrumental in the execution of our business plan and delivering shareholder value.”

Christopher Jarvis, 44, has over 20 years of capital markets and investments experience covering the equity, commodity, and fixed-income markets.  He engineered and executed energy risk management hedges for large multi-national companies and as a publishing analyst, he was ranked #1 by Bloomberg’s BARR analyst ranking system.  He has earned the designation of Chartered Financial Analyst (CFA) and Chartered Market Technician (CMT) and routinely appears on CNBC, Fox Business News, and Reuters.  He is a contributor to major print media outlets including Reuters, Bloomberg and the Wall Street Journal as an oil and gas analyst. Mr. Jarvis earned a B.A. in Art History from University of Massachusetts and M.B.A. from the University of Connecticut, with a concentration in Finance.  He is a member of the CFA Institute and also the Market Technician’s Association (MTA).  He has been a member of the University of Connecticut Financial Accelerator Advisory Board for the last 10 years and previously served as the Vice President of the Autism Society of New Hampshire (2004-09). In addition to assuming his full-time role with the Company, Christopher Jarvis will remain a Director of both Foothills Exploration and Foothills Petroleum Inc.

Kevin Sylla, 42, has served as Managing Director of Tiger Energy Operating, LLC and Tiger Energy Partners International, LLC for the past five years and he will continue in those roles for the foreseeable future.  Mr. Sylla played a key advisory role in the successful combination and integration of Tiger’s assets into Foothills Exploration.  He has over 10 years of oil & gas industry experience with extensive knowledge in business development, mergers and acquisitions, and management of oil and gas field operations.  Mr. Sylla has participated extensively in the financing, acquisition and development of numerous domestic oil and gas properties.  His acquisition experience has been focused on improving operating and financial efficiencies with underperforming assets resulting in enhanced value creation.  Mr. Sylla is the managing member of Wilshire Energy Partners, LLC, a principal shareholder of the Company and has provided consulting services to the Company since its formation.  During his career, Mr. Sylla has drilled, reworked and overseen the management of hundreds of wells.  Mr. Sylla completed the Petroleum Land Management Program at Texas Christian University and earned his Energy & Finance Management Certification from the University of Denver.

About the Company

Foothills Exploration, Inc. (OTCQB:FTXP), based in Denver, Colorado, is a growth stage oil and gas exploration and production (E&P) company with focus and expertise in acquisition and development of onshore and offshore properties.  The Company’s assets are located across well-established plays in the Rocky Mountain and Gulf Coast regions.  Please visit the Foothills website at http://ir.foothillspetro.com/.

Forward-Looking Statements

All statements, other than statements of historical facts, included in this release that address activities, events or developments that we expect, believe or anticipate will or may occur in the future are forward-looking statements.  These statements are based on certain assumptions we made based on management’s experience, perception of historical trends and technical analyses, current conditions, capital plans, drilling plans, production expectations, our abilities to raise adequate additional capital to support our acquisition, development and drilling activities, anticipated future developments, and other factors believed to be appropriate and reasonable by management.  When used in this release, words such as „will,” “possible,” „potential,” „believe,” „estimate,” „intend,” „expect,” „may,” „should,” „anticipate,” „could,” „plan,” „predict,” „project,” „profile,” „model,” „strategy,” „future” or their negatives or the statements that include these words or other words that convey the uncertainty of future events or outcomes, are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words.  In particular, statements, express or implied, concerning our future operating results and returns or our ability to acquire or develop proven or probable reserves, our ability to replace or increase reserves, increase production, or generate income or cash flows are forward-looking statements.

Forward-looking statements are not guarantees of performance. Such statements are subject to a number of assumptions, risks and uncertainties, many of which are beyond our control. While forward-looking statements are based on assumptions and analyses made by us that we believe to be reasonable under the circumstances, whether actual results and developments will meet our expectations and predictions depend on a number of risks and uncertainties which could cause our actual results, performance, and financial condition to differ materially from our expectations. As a result, no assurance can be given that these assumptions are accurate or that any of these expectations will be achieved (in full or at all) or will prove to have been correct.  Although we have recently commenced generating revenue, our securities are subject to considerable risk and widespread fluctuation.  Investors are cautioned to review FTXP’s filings with the Securities and Exchange Commission for a discussion of risk and other factors that affect our business.  Any forward-looking statement made by us in this news release speaks only as of the date on which it is made.  Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them.  We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future development or otherwise, except as may be required by law. 

Investor Contact

MZ Group
Derek Gradwell
SVP, Natural Resources
Email: dgradwell@mzgroup.us 
Tel: 512-270-6990
Web: www.mzgroup.com

Primary Logo

Copyright © 2017 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

Medicine Man Technologies Inc. (MDCL: OTCQB) | Medicine Man Technologies Agrees to Acquire Pono Publications and Success Nutrients

Mar 03, 2017

OTC Disclosure & News Service

Denver, Colorado, March 03, 2017 (GLOBE NEWSWIRE) — Medicine Man Technologies Inc. (OTCQB: MDCL), one of the country’s leading cannabis branding and consulting companies, announced today that it has entered into agreements to acquire both Pono Publications Ltd. and Success Nutrients, Inc., each a privately held Colorado corporation. Medicine Man has agreed to issue 7 million shares of its common stock as consideration for the acquisition, which represents approximately 40% interest in the Company.

As a part of this new acquisition, the Company has retained of Mr. Josh Haupt as its Chief Cultivation Officer, noting Mr. Haupt will serve as a key member of management, reporting to the Board of Directors which will now include Mr. Charley Haupt, Josh’s father a well-respected professional in the national energy management sector.

The Pono Publications Ltd brand includes the Three A Light™ cultivation book, along with the recently released professional-grade version developed in collaboration with MMT exclusively for both Three A Light™ and Medicine Man Technologies clients. This exceptional cultivation methodology is achieving significant results delivering annualized yields of cured cannabis of approximately 700-grams per square foot of flower canopy and is deployable in both greenhouse and indoor based cultivation facilities.

The Success Nutrients and Pono brands provide the key underpinnings of an enhanced cultivation methodology and is essential to the overall Three A Light™ performance metric. With an investment of two years of research, development and intense testing, this product line was specifically formulated for the cannabis industry and is producing significant results for its users throughout North America.

The synergy of these companies is expected to accelerate growth of all of the Company’s product and service lines, including the potential for increased revenues. As an example, the Company anticipates generating additional revenues from its recently announced new product line, Cultivation MAX. At the signing of a client’s new Cultivation MAX facility in Clark County Nevada this week, Mr. Josh Haupt stated, “This client’s five hundred plus light facility and planned expansions should enable us to generate a high six figure annual income starting later this summer, as we complete the integration of the Three A Light Professional Grade and Success Nutrient regimens.” However, there can be no assurances that these additional revenues will be generated.

Regarding the acquisition, Andy Williams, MMT’s CEO and co-founder noted, “We could not be more excited to welcome Pono Publications and Success Nutrients to the Medicine Man Technologies family. I believe Josh Haupt and Three A Light™ are the best industrial cultivators of cannabis in the world and are unmatched in their ability to produce quality, high-yielding crops. The complimentary nature of Pono and Success Nutrients to our existing practice has already created a new line of business and we believe will allow exponential growth on all fronts, establishing Medicine Man Technologies as the gold standard of cannabis cultivation.

Josh Haupt, principal and founder of Pono Publications and Success Nutrients stated, “After spending many years in development of both my proprietary nutrient line and cultivation methodologies, I am pleased to have found a new partnership opportunity that we believe will be mutually beneficial. The fact that Medicine Man Technologies is also a well-known presence in the cannabis industry should allow us to add substantial value back to the business as a whole while making more efficient use of our mutual resources.”

While no guarantees can be offered, the Company expects significant revenue growth with the addition with these two innovative business noting that during the first two months of operations in FY 2017, Pono Publications (Three A Light™) and Success Nutrients generated strong profitability on revenues in excess of $270,000, a trend the Company expects to continue under Mr. Haupt’s continued oversight.  

About Medicine Man Technologies, Inc.

Established in March 2014, the Company secured its first client/licensee in April 2014. To date, they have provided guidance for several clients that have successfully secured licenses to operate cannabis businesses within their state. It currently has twenty eight active clients in 12 states and Puerto Rico, focusing on working with clients to 1) utilize its experience, technology, and training to help secure a license in states with newly emerging regulations, 2) deploy the Company’s highly effective variable capacity constant harvest cultivation practices through its deployment of Cultivation MAX, and eliminate the liability of single grower dependence, 3) avoid the costly mistakes generally made in start-up, 4) stay engaged with an ever expanding team of licensees and partners, all focused on quality and safety that will ‚share’ the ever-improving experience and knowledge of the network, and 5) continuing the expansion of its Brands Warehouse concept.

Safe Harbor Statement

This press release may contain forward looking statements which are based on current expectations, forecasts, and assumptions that involve risks and uncertainties that could cause actual outcomes and results to differ materially from those anticipated or expected, including statements related to the amount and timing of expected revenues and any payment of dividends on our common and preferred stock, statements related to our financial performance, expected income, distributions, and future growth for upcoming quarterly and annual periods. These risks and uncertainties are further defined in filings and reports by the Company with the U.S. Securities and Exchange Commission (SEC).  Actual results and the timing of certain events could differ materially from those projected in or contemplated by the forward-looking statements due to a number of factors detailed from time to time in our filings with the Securities and Exchange Commission. Among other matters, the Medicine Man Technologies may not be able to sustain growth or achieve profitability based upon many factors including, but not limited to, general stock market conditions. Reference is hereby made to cautionary statements set forth in the company’s most recent SEC filings. We have incurred and will continue to incur significant expenses in our expansion of our existing and new service lines, noting there is no assurance that we will generate enough revenues to offset those costs in both the near and long term.  Additional service offerings may expose us to additional legal and regulatory costs and unknown exposure(s) based upon the various geopolitical locations where we will be providing services, the impact of which cannot be predicted at this time.

Contact Information:
 
Attention Brett Roper via info@medicinemantechnologies.com
 
Telephone (303) 371-0387

Copyright © 2017 GlobeNewswire. All Rights Reserved

The above news release has been provided by the above company via the OTC Disclosure and News Service. Issuers of news releases and not OTC Markets Group Inc. are solely responsible for the accuracy of such news releases.

National Psoriasis Foundation 2016 Medical Professional Awards Winners

PORTLAND, Ore., March 3, 2017 /PRNewswire-USNewswire/ — Recognized for their tireless work and commitment to better patient outcomes and promoting a cure for psoriasis and psoriatic arthritis, the National Psoriasis Foundation (NPF) is honored to announce the winners of the 2nd Annual NPF Medical Professional Awards. Nominated by patients and colleagues, award recipients are clinicians who have made a significant impact in the psoriatic disease community and have joined NPF in our mission to drive efforts toward finding a cure and improving the lives of those affected.

Selected by a committee of NPF medical board members, nominees were evaluated on specific criteria for each award, and their overall effort in improving the lives of those affected by psoriatic disease. NPF is pleased to recognize the following professionals.

Outstanding Educator in Psoriatic Disease, Joel M. Gelfand, M.D., MSCE.
Joel M. Gelfand is Professor of Dermatology and of Epidemiology at the University of Pennsylvania. He is a board-certified dermatologist whose clinical work focuses on general dermatology and psoriasis. He has created a multi-disciplinary approach to the care of psoriasis patients at Penn through his recruitment and mentoring of a rheumatologist and cardiologist who now specialize in systemic complications of psoriasis.

Outstanding Physician-Clinician, Alexa Boer Kimball, M.D., M.P.H
Alexa Boer Kimball, M.D., M.P.H. is the president and chief executive officer of Harvard Medical Faculty Physicians, an academic multi-specialty group employing more than 1,200 full-time Harvard Medical School faculty members and 450 physicians in the community. She is also President of the Beth Israel Deaconess Care Organization Physician LLC, which maintains a membership of approximately 2500 physicians, and a Professor of Dermatology at Harvard Medical School.

Dr. Kimball is an international expert on psoriasis and hidradenitis suppurativa who has published more than 250 peer-reviewed scientific papers and 100 Questions and Answers about Psoriasis, which has been translated into Spanish, Greek and Korean. In 2016 she was named Mentor of the Year by the Women’s Dermatologic Society.

Health Professional Volunteer of the Year Craig F. Teller, MD
Craig F. Teller, MD, is a native Houstonian and has been practicing dermatology since 1995. Board certified by the American Board of Dermatology and a fellow of the American Academy of Dermatology, Dr. Teller holds an academic appointment as Clinical Instructor of Dermatology in family medicine at Baylor College of Medicine as well as Clinical Instructor of Dermatology at the University of Texas Medical School in Houston. Dr. Teller is being recognized for his efforts and promotion of the NPF mission and key initiatives at the local division with strong contributions and support of the overall NPF goals and objectives.

Outstanding Allied Health, Lakshi Aldredge, MSN, ANP-BC
Ms. Lakshi Aldredge is a nurse practitioner who has practiced at the Portland VA Medical Center for the past 22 years, the last eight years in the medical Dermatology Service. Aldredge is being recognized for her outstanding achievements in improving psoriatic disease clinical practice and the quality of life of her patients. She is actively involved in the day-to-day clinical care of her patients and is nationally known for her exceptional clinical knowledge and expertise.

Aldredge is the past President of the national Dermatology Nurses’ Association (DNA) and is the current Chair of the Nurse Practitioner Society of the DNA. She is on the Advisory board of Dermatology World, is an Associate Editor of Psoriasis Forum, the peer-reviewed journal of the National Psoriasis Foundation, as well as a member of the Editorial Board of the Journal of the Dermatology Nurses’ Association.

Over the last 50 years, the National Psoriasis Foundation (NPF) has become the world’s leading nonprofit patient advocacy organization fighting for individuals with psoriasis and psoriatic arthritis. NPF leads this fight by driving efforts for a cure and improving the lives of the more than 8 million Americans affected by this chronic disease. To date, NPF has funded more than $15 million in research grants and fellowships, and to commemorate 50 years, NPF plans to raise an additional $2 million for early scientific career research programs in 2017 alone. Each year, NPF strives to support, educate and advocate on behalf of more individuals living with or caring for someone with the disease than ever before. As part of that effort, NPF established the Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. Join our community today and help drive discovery and create community for all living with psoriatic disease.

 

SOURCE National Psoriasis Foundation

National Psoriasis Foundation 2016 Medical Professional Awards Winners

PORTLAND, Ore., March 3, 2017 /PRNewswire-USNewswire/ — Recognized for their tireless work and commitment to better patient outcomes and promoting a cure for psoriasis and psoriatic arthritis, the National Psoriasis Foundation (NPF) is honored to announce the winners of the 2nd Annual NPF Medical Professional Awards. Nominated by patients and colleagues, award recipients are clinicians who have made a significant impact in the psoriatic disease community and have joined NPF in our mission to drive efforts toward finding a cure and improving the lives of those affected.

Selected by a committee of NPF medical board members, nominees were evaluated on specific criteria for each award, and their overall effort in improving the lives of those affected by psoriatic disease. NPF is pleased to recognize the following professionals.

Outstanding Educator in Psoriatic Disease, Joel M. Gelfand, M.D., MSCE.
Joel M. Gelfand is Professor of Dermatology and of Epidemiology at the University of Pennsylvania. He is a board-certified dermatologist whose clinical work focuses on general dermatology and psoriasis. He has created a multi-disciplinary approach to the care of psoriasis patients at Penn through his recruitment and mentoring of a rheumatologist and cardiologist who now specialize in systemic complications of psoriasis.

Outstanding Physician-Clinician, Alexa Boer Kimball, M.D., M.P.H
Alexa Boer Kimball, M.D., M.P.H. is the president and chief executive officer of Harvard Medical Faculty Physicians, an academic multi-specialty group employing more than 1,200 full-time Harvard Medical School faculty members and 450 physicians in the community. She is also President of the Beth Israel Deaconess Care Organization Physician LLC, which maintains a membership of approximately 2500 physicians, and a Professor of Dermatology at Harvard Medical School.

Dr. Kimball is an international expert on psoriasis and hidradenitis suppurativa who has published more than 250 peer-reviewed scientific papers and 100 Questions and Answers about Psoriasis, which has been translated into Spanish, Greek and Korean. In 2016 she was named Mentor of the Year by the Women’s Dermatologic Society.

Health Professional Volunteer of the Year Craig F. Teller, MD
Craig F. Teller, MD, is a native Houstonian and has been practicing dermatology since 1995. Board certified by the American Board of Dermatology and a fellow of the American Academy of Dermatology, Dr. Teller holds an academic appointment as Clinical Instructor of Dermatology in family medicine at Baylor College of Medicine as well as Clinical Instructor of Dermatology at the University of Texas Medical School in Houston. Dr. Teller is being recognized for his efforts and promotion of the NPF mission and key initiatives at the local division with strong contributions and support of the overall NPF goals and objectives.

Outstanding Allied Health, Lakshi Aldredge, MSN, ANP-BC
Ms. Lakshi Aldredge is a nurse practitioner who has practiced at the Portland VA Medical Center for the past 22 years, the last eight years in the medical Dermatology Service. Aldredge is being recognized for her outstanding achievements in improving psoriatic disease clinical practice and the quality of life of her patients. She is actively involved in the day-to-day clinical care of her patients and is nationally known for her exceptional clinical knowledge and expertise.

Aldredge is the past President of the national Dermatology Nurses’ Association (DNA) and is the current Chair of the Nurse Practitioner Society of the DNA. She is on the Advisory board of Dermatology World, is an Associate Editor of Psoriasis Forum, the peer-reviewed journal of the National Psoriasis Foundation, as well as a member of the Editorial Board of the Journal of the Dermatology Nurses’ Association.

Over the last 50 years, the National Psoriasis Foundation (NPF) has become the world’s leading nonprofit patient advocacy organization fighting for individuals with psoriasis and psoriatic arthritis. NPF leads this fight by driving efforts for a cure and improving the lives of the more than 8 million Americans affected by this chronic disease. To date, NPF has funded more than $15 million in research grants and fellowships, and to commemorate 50 years, NPF plans to raise an additional $2 million for early scientific career research programs in 2017 alone. Each year, NPF strives to support, educate and advocate on behalf of more individuals living with or caring for someone with the disease than ever before. As part of that effort, NPF established the Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. Join our community today and help drive discovery and create community for all living with psoriatic disease.

 

SOURCE National Psoriasis Foundation

National Psoriasis Foundation 2016 Medical Professional Awards Winners

PORTLAND, Ore., March 3, 2017 /PRNewswire-USNewswire/ — Recognized for their tireless work and commitment to better patient outcomes and promoting a cure for psoriasis and psoriatic arthritis, the National Psoriasis Foundation (NPF) is honored to announce the winners of the 2nd Annual NPF Medical Professional Awards. Nominated by patients and colleagues, award recipients are clinicians who have made a significant impact in the psoriatic disease community and have joined NPF in our mission to drive efforts toward finding a cure and improving the lives of those affected.

Selected by a committee of NPF medical board members, nominees were evaluated on specific criteria for each award, and their overall effort in improving the lives of those affected by psoriatic disease. NPF is pleased to recognize the following professionals.

Outstanding Educator in Psoriatic Disease, Joel M. Gelfand, M.D., MSCE.
Joel M. Gelfand is Professor of Dermatology and of Epidemiology at the University of Pennsylvania. He is a board-certified dermatologist whose clinical work focuses on general dermatology and psoriasis. He has created a multi-disciplinary approach to the care of psoriasis patients at Penn through his recruitment and mentoring of a rheumatologist and cardiologist who now specialize in systemic complications of psoriasis.

Outstanding Physician-Clinician, Alexa Boer Kimball, M.D., M.P.H
Alexa Boer Kimball, M.D., M.P.H. is the president and chief executive officer of Harvard Medical Faculty Physicians, an academic multi-specialty group employing more than 1,200 full-time Harvard Medical School faculty members and 450 physicians in the community. She is also President of the Beth Israel Deaconess Care Organization Physician LLC, which maintains a membership of approximately 2500 physicians, and a Professor of Dermatology at Harvard Medical School.

Dr. Kimball is an international expert on psoriasis and hidradenitis suppurativa who has published more than 250 peer-reviewed scientific papers and 100 Questions and Answers about Psoriasis, which has been translated into Spanish, Greek and Korean. In 2016 she was named Mentor of the Year by the Women’s Dermatologic Society.

Health Professional Volunteer of the Year Craig F. Teller, MD
Craig F. Teller, MD, is a native Houstonian and has been practicing dermatology since 1995. Board certified by the American Board of Dermatology and a fellow of the American Academy of Dermatology, Dr. Teller holds an academic appointment as Clinical Instructor of Dermatology in family medicine at Baylor College of Medicine as well as Clinical Instructor of Dermatology at the University of Texas Medical School in Houston. Dr. Teller is being recognized for his efforts and promotion of the NPF mission and key initiatives at the local division with strong contributions and support of the overall NPF goals and objectives.

Outstanding Allied Health, Lakshi Aldredge, MSN, ANP-BC
Ms. Lakshi Aldredge is a nurse practitioner who has practiced at the Portland VA Medical Center for the past 22 years, the last eight years in the medical Dermatology Service. Aldredge is being recognized for her outstanding achievements in improving psoriatic disease clinical practice and the quality of life of her patients. She is actively involved in the day-to-day clinical care of her patients and is nationally known for her exceptional clinical knowledge and expertise.

Aldredge is the past President of the national Dermatology Nurses’ Association (DNA) and is the current Chair of the Nurse Practitioner Society of the DNA. She is on the Advisory board of Dermatology World, is an Associate Editor of Psoriasis Forum, the peer-reviewed journal of the National Psoriasis Foundation, as well as a member of the Editorial Board of the Journal of the Dermatology Nurses’ Association.

Over the last 50 years, the National Psoriasis Foundation (NPF) has become the world’s leading nonprofit patient advocacy organization fighting for individuals with psoriasis and psoriatic arthritis. NPF leads this fight by driving efforts for a cure and improving the lives of the more than 8 million Americans affected by this chronic disease. To date, NPF has funded more than $15 million in research grants and fellowships, and to commemorate 50 years, NPF plans to raise an additional $2 million for early scientific career research programs in 2017 alone. Each year, NPF strives to support, educate and advocate on behalf of more individuals living with or caring for someone with the disease than ever before. As part of that effort, NPF established the Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. Join our community today and help drive discovery and create community for all living with psoriatic disease.

 

SOURCE National Psoriasis Foundation

Enigma Software Group Resolves Bleeping Computer Litigation

CLEARWATER, Florida, March 3, 2017 /PRNewswire/ — Enigma Software Group USA, LLC (“ESG”) announced that it reached a settlement in the lawsuit it filed last year against Bleeping Computer LLC. The case will now be dismissed. ESG filed suit against Bleeping Computer in federal court in New York on January 5, 2016. The complaint alleged false advertising, defamation, and related claims.

The terms of the settlement are confidential, but Bleeping Computer explained in its press release on the settlement that it has now removed the posts written by its staff member that gave rise to ESG’s lawsuit. All of Bleeping Computer’s counterclaims in the lawsuit will be dismissed by the court with prejudice, along with ESG’s dismissal of the case.

Bleeping Computer had moved to dismiss ESG’s lawsuit, alleging that its statements were protected by Section 230 of the Communications Decency Act. The court rejected that motion in a decision handed down last summer.

Ryan Gerding, a spokesman for ESG, said of the development, “ESG is pleased to put this matter behind us and to get back to making the best anti-malware products on the market. It is unfortunate when litigation becomes necessary, but ESG is grateful to the court for its assistance.”

About Enigma Software Group USA, LLC

Enigma Software Group USA, LLC is a privately held international systems integrator and developer of PC security software, with offices in the United States and the European Union. The company’s specialties are the development of PC security software, online security analysis, adaptive threat assessment, and detection of PC security threats, as well as malware custom fixes for its millions of subscribers worldwide. ESG is best known for SpyHunter®, its anti-malware software product and service. To learn more about ESG, visit www.enigmasoftware.com.

Connect with ESG on Twitter | Facebook | Google+ | LinkedIn | YouTube

Logo – http://mma.prnewswire.com/media/452052/Enigma_Software_Logo.jpg

SOURCE Enigma Software Group USA, LLC

Unlicensed Medical Professional Convicted for Role in $1.3 Million Medicare Fraud Scheme

A federal jury in Houston convicted an unlicensed medical professional who was posing as a physician yesterday for his participation in a $1.3 million Medicare fraud scheme. 

Acting Assistant Attorney General Kenneth A. Blanco of the Justice Department’s Criminal Division, U.S. Attorney Kenneth Magidson of the Southern District of Texas, Special Agent in Charge Perrye K. Turner of the FBI’s Houston Field Office and Special Agent in Charge C.J. Porter of the U.S. Department of Health and Human Services-Office of Inspector General’s (HHS-OIG) Dallas Regional Office made the announcement.
                                             
Rex Duruji, 56, of Houston, was convicted yesterday of one count of conspiracy to commit healthcare fraud, one count of conspiracy to pay healthcare kickbacks and one count of healthcare fraud following a four-day trial before U.S. District Judge Kenneth M. Hoyt of the Southern District of Texas.  Duruji is scheduled to be sentenced on May 8, 2017.

According to evidence presented at trial, from January 2012 until May 2015, Duruji engaged in a scheme to defraud Medicare by posing as a licensed physician, although he did not possess a medical license in the State of Texas.  The evidence presented at trial showed that Duruji posed as a physician to induce Medicare beneficiaries to sign up for fraudulent home-health services with Koby Home Health (Koby) that were not actually provided and paid illegal cash kickbacks to the beneficiaries for those claims.  According to evidence at trial, Medicare paid approximately $1.3 million in false and fraudulent claims for home-health services submitted by Koby.  

The FBI and HHS-OIG investigated the case.  Trial Attorneys Scott Armstrong and Kevin Lowell of the Criminal Division’s Fraud Section are prosecuting the case.